SCHEMBL30040396

SCHEMBL30040396

O=C(Nc1cccc(F)c1)c1cc(N2CCOCC2)nc(-n2ccnc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 12/20 0.65
RAF1 P04049 1/20 0.56
BRAF P15056 1/20 0.56
PIK3CD O00329 1/20 0.51
AKT1 P31749 1/20 0.51
PIK3CA P42336 1/20 0.51
PIK3CB P42338 1/20 0.51
CYP1A2 P05177 4/20 0.49
DGAT1 O75907 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
NFKB1 P19838 1/20 0.48
HTT P42858 1/20 0.48
NFKB2 Q00653 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30039521 0.92 CD38 (0.68) CD38RAF1BRAFCYP1A2SMN1; SMN2
SCHEMBL30040824 0.91 CD38 (0.67) CD38RAF1BRAFCYP1A2SMN1; SMN2
SCHEMBL30038853 0.80 CD38 (0.70) CD38RAF1BRAFCYP1A2CYP2C19
SCHEMBL30040233 0.79 CD38 (1.00) CD38RAF1BRAFCYP1A2CYP2C19
SCHEMBL30038885 0.79 CD38 (0.63) CD38CYP1A2SMN1; SMN2CYP2C19
SCHEMBL30040802 0.78 CD38 (1.00) CD38CYP1A2
SCHEMBL30038430 0.78 CD38 (0.71) CD38CYP1A2CYP2C19
SCHEMBL30040833 0.78 CD38 (0.71) CD38CYP1A2SMN1; SMN2CYP2C19
SCHEMBL30039685 0.78 CD38 (0.58) CD38CYP1A2NPC1RAB9AALDH1A1
SCHEMBL30039224 0.77 CD38 (0.49) CD38RAF1BRAFCYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254113-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS Nanjing Immunophage Biotech Co., Ltd. (CN) 2024-08-01 US claimed
WO-2022228496-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2022-11-03 WO claimed
US-20250382283-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) 2025-12-18 US disclosed
US-20240254113-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS Nanjing Immunophage Biotech Co., Ltd. (CN) 2024-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254113-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS CD38, CD22, BCL6B CD38 1/4885RAF1 1539/4885BRAF 2840/4885
US-20250382283-A1 COMPOUNDS AND THEIR USES AS CD38 INHIBITORS CD38, FCGRT, CD22 CD38 1/4885RAF1 1720/4885BRAF 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.